Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.
You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.
After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.
Physiological, pharmacological and molecular biological data generated over the past three decades have demonstrated the existence of two major families of extracellular receptors, the P1, a family of four G-protein coupled receptors and the P2, a family of at least 12 receptors responsive to purine (ATP, ADP) and pyrimidine (UTP) nucleotides through which adenosine and ATP can function as extracellular messengers. The present two-part volume represents an integrated compendium of invited chapters by leading researchers in the area focusing on advances in the understanding of purinergic and pyrimidinergic signaling systems, their role(s) in tissue function and pathophysiology and advances in developing potential new medications based on the modulation of P1 and P2 receptor signaling processes. The volumes will thus provide the reader with a topical, comprehensive and integrated overview of this important area.
16. P1 Reeptors in the Cardiovascular System. 17. P1 and P2 Receptors in the Renal System. 18. P2 Receptors in the Cardiovascular System. 19. Roles of Purines and Pyrimidines in Endothelium. 20. P1 and P2 Receptors in Platelets. 21. Purinergic Signalling in Gut. 22. P1 Receptors in the Respiratory System. 23. P2 Receptors in the Respiratory System. 24. Role of P1 Receptors in Inflamation. 25. Role of P2 Receptors in the Immune System. 26. On the Role of P2X7 Receptors in Immune System. 27. Purinergic Receptors and the Pharmacology of Type 2 Diabetes. 28. Purinergic and Pyrimidinergic Receptor Signalling in Bone Cells. 29. Clinical Opportunities in Purinergic Neuromodulation.